Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Stage IV Nasopharyngeal Carcinoma
Interventions
DRUG

cisplatin and 5-Fu combined with nimotuzumab

"DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week"

Trial Locations (1)

Unknown

Cancer Center, Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

Fujian Cancer Hospital

OTHER_GOV

collaborator

First People's Hospital of Foshan

OTHER

collaborator

People's Hospital of Guangxi Zhuang Autonomous Region

OTHER

collaborator

Guangxi Medical University

OTHER

collaborator

Guangzhou Medical University

OTHER

collaborator

Hubei Cancer Hospital

OTHER

collaborator

Hunan Provincial Cancer Hospital

UNKNOWN

collaborator

Hangzhou Cancer Hospital

OTHER

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

Tongji Hospital

OTHER

collaborator

Jiangxi Provincial Cancer Hospital

OTHER

collaborator

Affiliated Cancer Hospital of Shantou University Medical College

OTHER

collaborator

Wuhan University

OTHER

collaborator

Zhejiang Cancer Hospital

OTHER

lead

Sun Yat-sen University

OTHER

NCT01616849 - Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter